New vaccine effective against deadly viral pig disease
Researchers from Kansas State University's College of
Veterinary Medicine have developed a vaccine effective against a deadly viral
disease, most widely known as porcine circovirus associated disease, affecting
swine herds in Kansas.
The disease, first recognised in Kansas swine herds in
November 2005, is an immunosuppressive condition associated with porcine circovirus type 2 or PCV2
Swine producers with infected herds have experienced a death loss of 20
- 40% in finisher pigs, which are pigs between 10 - 20 weeks of age, resulting
in devastating economic losses.
The field trial began in 2006, directed by Dritz and Horlen testing a
vaccine in commercial development, was conducted on a family-owned swine farm in
northeast Kansas and concluded in January with promising results.
The study showed a 50% reduction in mortality of vaccinated pigs
compared to non-vaccinated pigs. Mortality was 7% for vaccinated pigs compared
to 17% for non-vaccinated pigs. Vaccinated pigs also experienced an increase in
growth. On average, they were 20 pounds (9kg) heavier than non-vaccinated pigs
of the same age. The vaccine is now commercially available.
"Results from this study suggest that the tested vaccine is effective
in controlling the PCV2 associated disease in pigs," said Rowland, a virologist
and associate professor of diagnostic medicine and pathobiology.
"We want to make it clear to swine producers that this vaccine licensed
by the US Department of Agriculture's Centre for Veterinary Biologics is safe
and effective," Rowland said.
To comment, login here
Or register to be able to comment.